ReviewTherapeutic innovation & regulatory science2026
Indian Pharmacopoeia Reference Standards: A Key Tool to Regulate the Quality of Pharmaceuticals.
Review in Therapeutic innovation & regulatory science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pharmacopoeia reference standards play a vital role in the pharmaceutical industry by setting benchmarks for the quality, purity and consistency of drugs. Established by official pharmacopeia bodies like British Pharmacopoeia Commission, European Pharmacopoeia Commission, Indian Pharmacopoeia Commission and United States Pharmacopeia; these standards provide the authoritative guidelines for analytical and quality control methods and ensure that pharmaceutical products worldwide meet regulatory requirements and remain safe for consumers. Despite their critical importance, the comprehensive scientific and regulatory processes involved in developing pharmacopoeial reference standards remain insufficiently documented in accessible literature, creating knowledge gaps for researchers, regulators and industry stakeholders. The current article addresses these gaps by detailing the key stages of pharmacopoeia reference standard development, drawing on the principles outlined in ISO 17034 (general requirements for the competence of reference material producers), ISO Guide 31 (covering the contents of certificates and labels for reference materials), ISO Guide 34 (general requirements for the competence of reference material producers), ISO/Guide 35:2017 (guidance on characterization and assessment of homogeneity and stability of reference materials) and WHO TRS 943 (general guidelines for the establishment, maintenance and distribution of chemical reference substances). Particular emphasis is placed on the development of Indian Pharmacopoeia Reference Standards, underscoring their pivotal role in analytical testing, method validation, quality control, and the broader framework of global pharmaceutical harmonization. Moreover, it elucidates how rigorous adherence to pharmacopoeial reference standards enables the pharmaceutical industry to ensure the safety and efficacy of medicinal products, thereby safeguarding public health and fostering sustained confidence in therapeutic interventions.
Indexed as
Identifiers
41606284What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.